What Fendrix Treats: Main Uses and Benefits

Fendrix is primarily used for active immunization to support the body's immunity against the Hepatitis B virus (HBV). This prophylactic approach contributes to reducing the risk of acute symptomatic illness and severe, long-term liver disease.

This vaccine is commonly used in conditions characterized by periods of heightened symptoms and physiological stress, specifically targeting adults and adolescents from 15 years who have renal insufficiency, including those undergoing haemodialysis and pre-dialysis care. This specific formulation is applied in these clinical settings to help these vulnerable patient groups achieve seroprotection, which is particularly relevant in patient groups where immune response may be less robust. It also is relevant for use when an individual is known to be among individuals where previous efforts to achieve immunity against HBV were unsuccessful or requires long-term maintenance of protective antibody levels.

“Fendrix provides specialized support for patients facing heightened risk, assisting with maintaining functional stability against future viral exposure.”

Quick Fact: Specialized Protection for Renal Patients

Quick Fact: Specialized Protection for Renal Insufficiency

Eligibility Map: Who can and cannot use Fendrix — official regulatory information

The official eligibility profile for Fendrix is strictly defined by government regulatory documents, outlining populations that are allowed, restricted, or contraindicated for use.

Eligibility scope	Official Regulatory Statement
Populations for whom use is allowed	Adolescents and adults from the age of 15 years onwards, including pre-haemodialysis and haemodialysis patients with renal insufficiency.
Populations for whom use is contraindicated	Individuals with known hypersensitivity (allergy) to the active substance, any excipients, or a history of allergic reaction to other hepatitis B vaccines.
Age-related eligibility rules	Minimum age is 15 years. Safety and efficacy have not been established in children aged less than 15 years.
Condition-specific eligibility rules	Fendrix is specifically indicated for patients with renal insufficiency. Patients with chronic liver disease, HIV infection, or who are hepatitis C carriers are not precluded from vaccination.
Pregnancy and lactation eligibility	Conditional Use: No clinical data are available; vaccination should only be performed if the risk-benefit ratio outweighs possible risks for the foetus/infant.
Eligibility-related restrictions	Administration must be postponed in subjects suffering from acute severe febrile illness. The vaccine may result in an inadequate immune response in patients receiving immunosuppressive treatment or those with immunodeficiency.

---

Eligibility Classifications (High-Level)

Eligibility scope	Classification
Severity Classification	Contraindication (Hypersensitivity), Conditional Use (Pregnancy/Lactation), Postponement (Acute severe febrile illness), Not Established (Under 15 years).

---

Connection to the overall eligibility profile Official regulatory documents define the eligible population as adults and adolescents aged 15 years and above who have renal insufficiency. Non-eligibility is explicitly stated as an absolute contraindication in cases of known hypersensitivity. Restrictions apply to acute severe illness (postponement) and pregnancy/lactation (conditional use), reflecting the official requirements for use.

Fendrix: Interactions with other medicines and products

The official regulatory documentation for Fendrix strictly defines interaction patterns related to administration and potential impact on immune response.

---

Pharmacodynamic Interactions and Immunization

The product's effectiveness may be affected by certain concomitant medications. The presence of immunodeficiency or the use of immunosuppressive treatments is officially noted as a factor that may result in an inadequate immune response. This documented pharmacodynamic interaction means that the intended level of seroprotection against the Hepatitis B virus might not be fully achieved in this population.

---

Administration Restrictions and Separation

An absolute administrative prohibition is stated: Fendrix must not be mixed with any other medicinal product in the same syringe due to a lack of compatibility studies. Furthermore, timing and site separation are required for certain co-administrations. When administering Fendrix alongside other vaccines lacking co-administration data, an interval of 2 to 3 weeks should be respected. If Specific Hepatitis B Immunoglobulin (HBIg) is required simultaneously, regulatory documents mandate that the two products must be given at different injection sites. The official label does not specify any pharmacokinetic or transporter-mediated interactions, nor are interactions with food, alcohol, or herbal products documented.

Fendrix is a non-infectious, subunit vaccine formulation designed to modulate the immune system by presenting the HBsAg (Hepatitis B surface antigen) to antigen-presenting cells (APCs), primarily dendritic cells and macrophages, in the context of the AS03 adjuvant system.

The AS03 adjuvant component facilitates the targeted delivery of HBsAg and induces localized innate immune activation at the injection site. This involves the TLR4 agonist interaction of squalene and alpha-tocopherol with pattern recognition receptors, leading to the activation of the NF-kappa B signaling pathway within APCs. This pathway subsequently drives the transcriptional upregulation of pro-inflammatory cytokines and costimulatory molecules.

Following antigen uptake and maturation, APCs migrate to secondary lymphoid organs, presenting the HBsAg peptides via MHC Class II molecules to naive CD4^+ T-helper cells. The synergistic signal from the antigen/MHC-II complex and costimulatory molecules leads to the clonal expansion and differentiation of antigen-specific CD4^+ T-helper cells into various effector subsets. These activated CD4^+ T-helper cells then provide the necessary co-stimulation to B-lymphocytes, promoting their differentiation into plasma cells and memory B cells, thereby initiating the system-level physiological consequence of humoral immunity characterized by the production of anti-HBs antibodies.

Administration Overview

Fendrix is a vaccine administered via intramuscular injection. The procedure is typically performed by a healthcare professional, such as a doctor or nurse. The injection site is usually the deltoid muscle of the upper arm.

Preparation for Administration

The vaccine appears as a turbid white suspension. Prior to use, the container is shaken to ensure a homogenous distribution of the contents. The suspension is inspected visually for any foreign particulate matter or discoloration before it is administered.

Vaccination Schedule

The vaccination process consists of several individual doses administered over a specific period. This series is designed to stimulate the body's immune response. For individuals who are undergoing or about to undergo hemodialysis, the schedule is adapted to ensure optimal exposure to the vaccine components.

Specific Considerations

Intramuscular Route

The vaccine must be injected into the muscle. Alternative routes of administration, such as subcutaneous or intradermal injection, are generally avoided as they may result in a suboptimal immune response.

Handling and Disposal

Any unused vaccine or waste material is disposed of in accordance with local requirements for biological materials. The vaccine should not be mixed with other vaccines in the same syringe.

Research Evidence / Overview of Studies for Fendrix

Fendrix was studied for active immunization against the Hepatitis B virus (HBV). The research was applied in studies examining adult and adolescent populations who may have a lower immune response in general. The evidence collected helps contextualize how patients reported their experience and how immune responses evolved in the observed populations during the studies.

---

Evidence for Use in Patients with Renal Insufficiency

This section will summarize the core research supporting the licensed use of Fendrix, focusing on the design and scope of the clinical trials that examined seroprotection rates in adolescents and adults with chronic kidney disease, including those on haemodialysis.

The main body of evidence was studied in adolescents and adults (age 15 and older) with renal insufficiency, including those in pre-dialysis care or undergoing haemodialysis. These conditions are characterized by functional limitations where the body’s ability to mount a robust immune response to vaccination may be lower. The research included Randomized Controlled Trials (RCTs) alongside long-term observational studies.

In these studies, researchers focused on an outcome related to systemic or functional imbalance known as the Seroprotection Rate (SPR). This outcome measures the percentage of participants who developed a specific measured level of Anti-HBs antibodies one month after the primary course was finished. The findings describe patterns observed in the studies, reporting that a high percentage of patients reached the seroprotection level measured in the studied groups.

What remains uncertain is that the research is narrowly concentrated on the renal insufficiency population (haemodialysis and pre-dialysis). The results apply only to the populations studied, meaning the research does not determine whether an individual from a different, unstudied high-risk group will respond similarly.

---

Durability and Long-Term Antibody Persistence Studies

This section will describe the duration of follow-up documented in the official research, summarizing what the studies investigated regarding the maintenance of measured antibody levels and the persistence of the immune response over intermediate and long-term periods.

Research was studied for how long the measured antibody levels remained at the target threshold after the final dose. This involved dedicated long-term follow-up studies where researchers monitored the antibody levels at defined time intervals, tracking persistence up to three years (36 months) after the final dose.

What remains uncertain is that follow-up durations were limited. Long-term effects are not fully established, and there is limited information for long-term outcomes on antibody persistence and the overall need for future additional doses beyond three years.

Common questions about Fendrix (FAQ)

Q: What is the main difference between Fendrix and other similar hepatitis B products?

Fendrix is officially described as containing a specialized AS04C adjuvant system, which is designed to enhance the body's immune response to the vaccine's active component. This adjuvant is different from the conventional aluminum-based adjuvants found in some other Hepatitis B vaccines. Additionally, official documents highlight that Fendrix is specifically licensed for individuals 15 years and older who have renal insufficiency.

Q: Does Fendrix only work for the specific population it was originally studied in?

Official information confirms Fendrix is licensed for and was primarily studied in adolescents and adults aged 15 years and above with renal insufficiency. Regulatory documents emphasize that the research results are based on the population studied. Furthermore, official sources note that the immune response to any Hepatitis B vaccine can be affected by various factors, including the presence of certain chronic diseases.

Q: How long does the protective effect of Fendrix last after the full series?

Studies have monitored the measured antibody levels in the studied populations for up to three years (36 months) following the final dose of the primary course. During this period, a majority of patients maintained a protective antibody level. Regulatory documents indicate that the long-term effects on antibody persistence beyond three years are not yet fully established.

Q: Can individuals with chronic health issues generally use Fendrix?

Official regulatory information specifies Fendrix is indicated for patients with renal insufficiency. The official label also notes that individuals with other chronic health conditions, such as chronic liver disease, HIV infection, or hepatitis C, are generally not precluded from receiving the vaccine.

Q: Is Fendrix approved for use in most major global markets?

Fendrix is authorized for use within the European Union under the review of the European Medicines Agency (EMA). Official information regarding authorization in other major global regulatory territories, such as the US, Canada, or Japan, is typically determined and listed separately by each country's respective governmental body.

Q: Are there any observational studies on Fendrix conducted since its market authorization?

Official regulatory processes require continuous monitoring of Fendrix after it is authorized for use. This involves the review of data from various clinical settings and follow-up studies to observe and track long-term safety and the persistence of antibody levels over time.

Q: What does the term 'adjuvant' mean when related to the Fendrix formula?

An adjuvant is a component added to a vaccine that is intended to improve the body’s immune response to the active substance. Official documents confirm that Fendrix includes a specific adjuvant system, which is included to enhance the immune response to the antigen.

Q: Is a booster dose of Fendrix required after the initial course?

Regulatory documents indicate that a precautionary attitude should be considered regarding a booster dose, which is intended to ensure protective antibody levels are maintained. The necessity and timing of any booster is typically informed by relevant national recommendations and guidelines. Fendrix is also licensed for use as a booster dose after an initial primary vaccination course.

Q: What happens if a recommended dose of Fendrix is missed or delayed?

If a dose of Fendrix is missed or delayed, official patient information indicates a healthcare professional should be consulted promptly to arrange the next visit. Regulatory information indicates the complete course of four injections should be finished, as failure to do so may mean the intended protection against the disease is not fully achieved.

Q: Does Fendrix carry any documented long-term safety risks?

Official regulatory documents classify known adverse reactions by frequency, noting that most are mild and resolve quickly. Available safety data, which includes post-marketing reviews, has shown no consistent evidence of any serious long-term safety consequences associated with the use of the vaccine.

Q: Are there specific warnings or precautions for older adults receiving Fendrix?

Official documentation states that factors like older age have been observed to potentially reduce the immune response to Hepatitis B vaccines in general. This means that older adults may potentially have a lower level of protection after vaccination, although this is noted as a general factor and not a specific safety warning.

Q: What is the meaning of the microgram (mcg) unit mentioned in the Fendrix dosage information?

The microgram (µg or mcg) is a unit of measurement used to specify the exact amount of the active ingredient in each dose. For Fendrix, this unit measures the quantity of the Hepatitis B surface antigen (HBsAg), which is the component that stimulates the immune system.

Q: Why must Fendrix be administered by a qualified healthcare professional?

Fendrix must be administered by a qualified healthcare professional because it is a prescription-only injectable suspension. This is required to uphold the standards for correct intramuscular (IM) injection technique and proper preparation. Additionally, immediate medical supervision is required in the unlikely event of a rare or severe adverse reaction.

How to Store and Dispose of Fendrix

Fendrix suspension for injection must be stored under controlled conditions to maintain its efficacy and stability, as required by regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Refrigerated storage between 2 C and 8 C.
Freezing	Do not freeze; freezing destroys the vaccine and renders it unusable.
Protection	Store in the original package to protect the suspension from light.
Child Safety	Keep out of the reach and sight of children.

---

Disposal

Any unused medicinal product or associated waste materials must be disposed of in accordance with local requirements. The vaccine should not be discarded via wastewater systems or routine household trash.